Quinpirole and 8-OH-DPAT induce compulsive checking behavior in male rats by acting on different functional parts of an OCD neurocircuit

Behavioural Pharmacology

Volumn 24, Issue 1, 2013, Pages 65-73

  Alkhatib, Ahmad H ^a   Dvorkin Gheva, Anna ^a   Szechtman, Henry ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

compulsive checking behavior; dopamine serotonin interaction; obsessive compulsive disorder; rat; security motivation

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; QUINPIROLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPULSION; CONTROLLED STUDY; LOCOMOTION; MALE; NERVE CELL NETWORK; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OPEN FIELD BEHAVIOR; OPEN FIELD TEST; RAT; SENSITIZATION; STEREOTYPY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; COMPULSIVE BEHAVIOR; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; DRUG INTERACTIONS; MALE; NERVE TISSUE PROTEINS; NEURONS; OBSESSIVE-COMPULSIVE DISORDER; QUINPIROLE; RANDOM ALLOCATION; RATS; RATS, LONG-EVANS; SEROTONERGIC NEURONS; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN 5-HT3 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS; SPATIAL BEHAVIOR;

EID: 84872075489     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32835d5b7a     Document Type: Article

References (59)

1. Albert PR, Le François B (2010). Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front Neurosci 4:Article 35.
2. Alex KD, Pehek EA (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296-320.
3. Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, et al. (2004). Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol 72:195-221.
4. Barnes NM, Sharp T (1999). A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
5. Baxter LR Jr. (1992). Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am 15:871-884.
6. Beerepoot P, Lam V, Luu A, Tsoi B, Siebert D, Szechtman H (2008). Effects of salvinorin A on locomotor sensitization to D2/D3 dopamine agonist quinpirole. Neurosci Lett 446:101-104.
7. Ben Pazi A, Szechtman H, Eilam D (2001). The morphogenesis of motor rituals in rats treated chronically with the dopamine agonist quinpirole. Behav Neurosci 115:1301-1317.
8. Boyer P, Lienard P (2006). Why ritualized behavior? Precaution systems and action parsing in developmental, pathological and cultural rituals. Behav Brain Sci 29:595-613.
9. Canadian Council on Animal Care (1993). Guide to the care and use of experimental animals. Vol. 1. 2nd ed. Ottawa, Ontario: CCAC.
10. Djodari-Irani A, Klein J, Banzhaf J, Joel D, Heinz A, Harnack D, et al. (2011). Activity modulation of the globus pallidus and the nucleus entopeduncularis affects compulsive checking in rats. Behav Brain Res 219:149-158.
11. Drai D, Golani I (2001). SEE: a tool for the visualization and analysis of rodent exploratory behavior. Neurosci Biobehav Rev 25:409-426.
12. Drai D, Benjamini Y, Golani I (2000). Statistical discrimination of natural modes of motion in rat exploratory behavior. J Neurosci Methods 96:119-131.
13. Dvorkin A, Perreault ML, Szechtman H (2006). Development and temporal organization of compulsive checking induced by repeated injections of the dopamine agonist quinpirole in an animal model of obsessive-compulsive disorder. Behav Brain Res 169:303-311.
14. Dvorkin A, Silva C, McMurran T, Bisnaire L, Foster J, Szechtman H (2010). Features of compulsive checking behavior mediated by nucleus accumbens and orbital frontal cortex. Eur J Neurosci 32:1552-1563.
15. Ebdon D (1985). Statistics in geography. 2nd ed. Rev. with 17 programs. Oxford, Oxfordshire: B. Blackwell.
16. Eilam D, Golani I (1989). Home base behavior of rats (Rattus norvegicus) exploring a novel environment. Behav Brain Res 34:199-211.
17. Eilam D, Szechtman H (2005). Psychostimulant-induced behavior as an animal model of obsessive-compulsive disorder: an ethological approach to the form of compulsive rituals. CNS Spectr 10:191-202.
18. Einat H, Szechtman H (1995). Perseveration without hyperlocomotion in a spontaneous alternation task in rats sensitized to the dopamine agonist quinpirole. Physiol Behav 57:55-59.
19. Feygin DL, Swain JE, Leckman JF (2006). The normalcy of neurosis: evolutionary origins of obsessive-compulsive disorder and related behaviors. Prog Neuropsychopharmacol Biol Psychiatry 30:854-864.
20. Fink KB, Gö thert M (2007). 5-HT receptor regulation of neurotransmitter release. Pharmacol Rev 59:360-417.
21. Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. (2005). Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162:151-161.
22. Golani I, Benjamini Y, Eilam D (1993). Stopping behavior: constraints on exploration in rats (Rattus norvegicus). Behav Brain Res 53:21-33.
23. Graybiel AM, Rauch SL (2000). Toward a neurobiology of obsessive-compulsive disorder. Neuron 28:343-347.
24. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, et al. (2006). Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 31: 2384-2393.
25. Hayes DJ, Greenshaw AJ (2011). 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev 35:1419-1449.
26. Hen I, Sakov A, Kafkafi N, Golani I, Benjamini Y (2004). The dynamics of spatial behavior: how can robust smoothing techniques help? J Neurosci Methods 133:161-172.
27. Hinds AL, Woody EZ, Van Ameringen M, Schmidt LA, Szechtman H (2012). When too much is not enough: obsessive-compulsive disorder as a pathology of stopping, rather than starting. PLoS One 7:e30586.
28. Hoffman KL (2011). Animal models of obsessive compulsive disorder: recent findings and future directions. Expert Opin Drug Discov 6:725-737.
29. Huey ED, Zahn R, Krueger F, Moll J, Kapogiannis D, Wassermann EM, et al. (2008). A psychological and neuroanatomical model of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 20:390-408.
30. Insel TR (1992). Neurobiology of obsessive compulsive disorder: a review. Int Clin Psychopharmacol 7 (Suppl 1):31-33.
31. Joel D (2006). Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 30:374-388.
32. Korff S, Harvey BH (2006). Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology. Psychiatr Clin North Am 29:371-390.
33. Lundberg S, Carlsson A, Norfeldt P, Carlsson ML (2004). Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 28:1195-1199.
34. Man J, Hudson AL, Ashton D, Nutt DJ (2004). Animal models for obsessive-compulsive disorder. Curr Neuropharmacol 2:169-181.
35. Modell JG, Mountz JM, Curtis GC, Greden JF (1989). Neurophysiologic dysfunction in basal ganglia/limbic striatal and thalamocortical circuits as a pathogenetic mechanism of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 1:27-36.
36. Mundt A, Klein J, Joel D, Heinz A, Djodari-Irani A, Harnack D, et al. (2009). High-frequency stimulation of the nucleus accumbens core and shell reduces quinpirole-induced compulsive checking in rats. Eur J Neurosci 29: 2401-2412.
37. Noldus LP, Spink AJ, Tegelenbosch RA (2001). EthoVision: a versatile video tracking system for automation of behavioral experiments. Behav Res Methods InstrumComput 33:398-414.
38. Perreault ML, Graham D, Bisnaire L, Simms J, Hayton S, Szechtman H (2005). Kappa-opioid agonist U69593 potentiates locomotor sensitization to the D2/D3 agonist quinpirole: pre-and postsynaptic mechanisms. Neuropsychopharmacology 31:1967-1981.
39. Salin-Pascual RJ, Basanez-Villa E (2003). Changes in compulsion and anxiety symptoms with nicotine transdermal patches in non-smoking obsessive-compulsive disorder patients. Rev Invest Clin 55:650-654.
40. Saxena S, Bota RG, Brody AL (2001). Brain-behavior relationships in obsessive-compulsive disorder. Semin Clin Neuropsychiatry 6:82-101.
41. Spink AJ, Tegelenbosch RA, Buma MO, Noldus LP (2001). The EthoVision video tracking system-a tool for behavioral phenotyping of transgenic mice. Physiol Behav 73:731-744.
42. Stein DJ (2002). Obsessive-compulsive disorder. Lancet 360:397-405.
43. Szechtman H, Eilam D (2005). Psychiatric models. In: Whishaw IQ, Kolb B, editors. The behavior of the laboratory rat: a handbook with tests. New York: Oxford University Press; pp. 462-474.
44. Szechtman H, Woody E (2004). Obsessive-compulsive disorder as a disturbance of security motivation. Psychol Rev 111:111-127.
45. Szechtman H, Dai H, Mustafa S, Einat H, Sullivan RM (1994a). Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 48:921-928.
46. Szechtman H, Talangbayan H, Canaran G, Dai H, Eilam D (1994b). Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy control mechanism [published erratum appears in Psychopharmacology (Berl) 1994;116(1):124]. Psychopharmacology (Berl) 115:95-104.
47. Szechtman H, Sulis W, Eilam D (1998). Quinpirole induces compulsive checking behavior in rats: a potential animal model of obsessive-compulsive disorder (OCD). Behav Neurosci 112:1475-1485.
48. Szechtman H, Eckert MJ, Tse WS, Boersma JT, Bonura CA, McClelland JZ, et al. (2001). Compulsive checking behavior of quinpirole-sensitized rats as an animal model of obsessive-compulsive disorder (OCD): form and control. Bmc Neurosci 2:4.
49. Szumlinski KK, Allan M, Talangbayan H, Tracey A, Szechtman H (1997). Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology (Berl) 134:193-200.
50. Tizabi Y, Louis VA, Taylor CT, Waxman D, Culver KE, Szechtman H (2002). Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol Psychiatry 51:164-171.
51. Vermeire S, Audenaert K, De Meester R, Vandermeulen E, Waelbers T, De Spiegeleer B, et al. (2012). Serotonin 2A receptor, serotonin transporter and dopamine transporter alterations in dogs with compulsive behaviour as a promising model for human obsessive-compulsive disorder. Psychiat Res-Neuroimag 201:78-87.
52. Westenberg HG, Fineberg NA, Denys D (2007). Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 12 (Suppl 3):14-27.
53. Whishaw IQ, Gharbawie OA, Clark BJ, Lehmann H (2006). The exploratory behavior of rats in an open environment optimizes security. Behav Brain Res 171:230-239.
54. Winter C, Flash S, Klavir O, Klein J, Sohr R, Joel D (2008). The role of the subthalamic nucleus in 'compulsive' behavior in rats. Eur J Neurosci 27:1902-1911.
55. Wise S, Rapoport JL (1989). Obsessive compulsive disorder-is it a basal ganglia dysfunction? In: Rapoport J, editor. Obsessive compulsive disorder in children and adolescence. Washington, DC: American Psychiatric Press; pp. 327-344.
56. Woody EZ, Szechtman H (2005). Motivation, time course, and heterogeneity in obsessive-compulsive disorder: response to Taylor, McKay, and Abramowitz. Psychol Rev 112:658-661.
57. Woody EZ, Szechtman H (2011). Adaptation to potential threat: the evolution, neurobiology, and psychopathology of the security motivation system. Neurosci Biobehav Rev 35:1019-1033.
58. Yadin E, Friedman E, Bridger WH (1991). Spontaneous alternation behavior: an animal model for obsessive-compulsive disorder? Pharmacol Biochem Behav 40:311-315.
59. Zadicario P, Ronen S, Eilam D (2007). Modulation of quinpirole-induced compulsive-like behavior in rats by environmental changes: implications for OCD rituals and for exploration and navigation. Bmc Neurosci 8:23.